Annual EBIT
-$138.04 M
+$23.63 M+14.62%
31 December 2023
Summary:
Adaptimmune Therapeutics annual earnings before interest & taxes is currently -$138.04 million, with the most recent change of +$23.63 million (+14.62%) on 31 December 2023. During the last 3 years, it has fallen by -$4.63 million (-3.47%). ADAP annual EBIT is now -1378.40% below its all-time high of -$9.29 million.ADAP EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$15.68 M
-$86.25 M-122.21%
30 September 2024
Summary:
Adaptimmune Therapeutics quarterly earnings before interest & taxes is currently -$15.68 million, with the most recent change of -$86.25 million (-122.21%) on 30 September 2024. Over the past year, it has increased by +$29.24 million (+65.10%). ADAP quarterly EBIT is now -122.21% below its all-time high of $70.57 million, reached on 30 June 2024.ADAP Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$68.44 M
+$29.24 M+29.93%
30 September 2024
Summary:
Adaptimmune Therapeutics TTM earnings before interest & taxes is currently -$68.44 million, with the most recent change of +$29.24 million (+29.93%) on 30 September 2024. Over the past year, it has increased by +$18.77 million (+21.52%). ADAP TTM EBIT is now -1614.50% below its all-time high of -$3.99 million, reached on 30 September 2014.ADAP TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADAP EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +14.6% | +65.1% | +21.5% |
| 3 y3 years | -3.5% | +62.8% | +56.4% |
| 5 y5 years | -67.6% | +60.9% | +51.6% |
ADAP EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -3.5% | +14.9% | -122.2% | +78.8% | at high | +63.8% |
| 5 y | 5 years | -67.6% | +14.9% | -122.2% | +78.8% | at high | +63.8% |
| alltime | all time | -1378.4% | +14.9% | -122.2% | +78.8% | -1614.5% | +63.8% |
Adaptimmune Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$15.68 M(-122.2%) | -$68.44 M(-29.9%) |
| June 2024 | - | $70.57 M(-243.3%) | -$97.68 M(-48.3%) |
| Mar 2024 | - | -$49.26 M(-33.5%) | -$188.96 M(+38.6%) |
| Dec 2023 | -$138.04 M(-14.6%) | -$74.08 M(+64.9%) | -$136.34 M(+56.3%) |
| Sept 2023 | - | -$44.91 M(+116.9%) | -$87.21 M(+2.3%) |
| June 2023 | - | -$20.71 M(-716.5%) | -$85.28 M(-21.3%) |
| Mar 2023 | - | $3.36 M(-113.5%) | -$108.33 M(-33.0%) |
| Dec 2022 | -$161.67 M(-0.4%) | -$24.95 M(-42.0%) | -$161.67 M(-10.0%) |
| Sept 2022 | - | -$42.99 M(-1.7%) | -$179.59 M(+0.5%) |
| June 2022 | - | -$43.75 M(-12.5%) | -$178.78 M(+2.5%) |
| Mar 2022 | - | -$49.98 M(+16.6%) | -$174.34 M(+7.5%) |
| Dec 2021 | -$162.25 M(+21.6%) | -$42.86 M(+1.6%) | -$162.25 M(+3.4%) |
| Sept 2021 | - | -$42.18 M(+7.3%) | -$156.90 M(+4.2%) |
| June 2021 | - | -$39.31 M(+3.8%) | -$150.59 M(+6.4%) |
| Mar 2021 | - | -$37.89 M(+1.0%) | -$141.53 M(+6.1%) |
| Dec 2020 | -$133.41 M(-4.6%) | -$37.51 M(+4.6%) | -$133.41 M(+5.7%) |
| Sept 2020 | - | -$35.88 M(+18.6%) | -$126.25 M(-3.3%) |
| June 2020 | - | -$30.25 M(+1.6%) | -$130.49 M(-3.9%) |
| Mar 2020 | - | -$29.76 M(-1.9%) | -$135.74 M(-2.9%) |
| Dec 2019 | -$139.77 M | -$30.36 M(-24.3%) | -$139.77 M(-1.2%) |
| Sept 2019 | - | -$40.12 M(+13.0%) | -$141.52 M(+49.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | -$35.50 M(+5.1%) | -$94.38 M(+7.5%) |
| Mar 2019 | - | -$33.79 M(+5.3%) | -$87.76 M(+6.1%) |
| Dec 2018 | -$82.36 M(+2.1%) | -$32.11 M(-557.5%) | -$82.70 M(+3.0%) |
| Sept 2018 | - | $7.02 M(-124.3%) | -$80.30 M(-13.0%) |
| June 2018 | - | -$28.88 M(+0.5%) | -$92.28 M(+5.8%) |
| Mar 2018 | - | -$28.74 M(-3.2%) | -$87.18 M(+8.1%) |
| Dec 2017 | -$80.66 M(+10.8%) | -$29.70 M(+498.8%) | -$80.66 M(+18.5%) |
| Sept 2017 | - | -$4.96 M(-79.1%) | -$68.05 M(-16.5%) |
| June 2017 | - | -$23.78 M(+7.0%) | -$81.48 M(+2.5%) |
| Mar 2017 | - | -$22.22 M(+30.0%) | -$79.50 M(+7.3%) |
| Dec 2016 | -$72.80 M(+175.6%) | -$17.09 M(-7.1%) | -$74.11 M(+30.0%) |
| Sept 2016 | - | -$18.39 M(-15.6%) | -$57.02 M(+16.5%) |
| June 2016 | - | -$21.80 M(+29.6%) | -$48.92 M(+80.4%) |
| Mar 2016 | - | -$16.82 M(+63.4%) | -$27.12 M(+126.9%) |
| Dec 2015 | -$26.41 M(+7.2%) | - | - |
| Sept 2015 | - | -$10.30 M(+522.1%) | -$11.95 M(+111.6%) |
| June 2015 | -$24.64 M(+113.9%) | - | - |
| Dec 2014 | - | -$1.65 M(-58.5%) | -$5.65 M(+41.5%) |
| Sept 2014 | - | -$3.99 M | -$3.99 M |
| June 2014 | -$11.52 M(+23.4%) | - | - |
| June 2013 | -$9.34 M | - | - |
FAQ
- What is Adaptimmune Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual EBIT year-on-year change?
- What is Adaptimmune Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly EBIT year-on-year change?
- What is Adaptimmune Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics TTM EBIT year-on-year change?
What is Adaptimmune Therapeutics annual earnings before interest & taxes?
The current annual EBIT of ADAP is -$138.04 M
What is the all time high annual EBIT for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual earnings before interest & taxes is -$9.29 M
What is Adaptimmune Therapeutics annual EBIT year-on-year change?
Over the past year, ADAP annual earnings before interest & taxes has changed by +$23.63 M (+14.62%)
What is Adaptimmune Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of ADAP is -$15.68 M
What is the all time high quarterly EBIT for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly earnings before interest & taxes is $70.57 M
What is Adaptimmune Therapeutics quarterly EBIT year-on-year change?
Over the past year, ADAP quarterly earnings before interest & taxes has changed by +$29.24 M (+65.10%)
What is Adaptimmune Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of ADAP is -$68.44 M
What is the all time high TTM EBIT for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high TTM earnings before interest & taxes is -$3.99 M
What is Adaptimmune Therapeutics TTM EBIT year-on-year change?
Over the past year, ADAP TTM earnings before interest & taxes has changed by +$18.77 M (+21.52%)